Revolution Medicines Q1 net loss widens on higher expenses

Revolution Medicines

06/05/2026 21:17

Overview

US oncology drug developer's Q1 net loss widened on higher R&D and G&A expenses

Company raised $2.2 bln in gross proceeds from April public offerings

Positive Phase 3 data for daraxonrasib in pancreatic cancer to be submitted to regulators

Outlook

Company updates 2026 GAAP operating expenses guidance to $1.7-$1.8 bln

Company expects 2026 stock-based compensation expense between $260-$280 mln

Company plans to submit daraxonrasib pivotal trial data to global regulatory authorities in 2026

Result Drivers

R&D SPENDING - Co said higher clinical trial and manufacturing expenses for daraxonrasib and zoldonrasib, along with increased personnel-related costs, drove up R&D expenses

STOCK-BASED COMPENSATION - Co said changes to its equity compensation program, including new retirement benefits, led to increased and accelerated stock-based compensation expense

COMMERCIAL PREPARATION - Co said higher G&A expenses were partly due to increased commercial preparation activities and administrative costs

Company press release: ID:nGNX97Bj23

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$2.29
Q1 Net Income
-$453.82 mln
Q1 Operating Expenses
$445.22 mln
Q1 Operating Income
-$445.22 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Revolution Medicines Inc is $171.00, about 16.2% above its May 5 closing price of $147.21

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)